← Back to Search

Laser Therapy

Low-Level Laser Therapy for Diabetic Foot Pain

N/A
Recruiting
Research Sponsored by Erchonia Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 3 weeks

Summary

This trial will test whether the Erchonia EVRL machine can provide relief from foot pain caused by diabetic neuropathy.

Who is the study for?
Adults over 18 with diabetic neuropathy who've had constant foot pain for at least 3 months can join. They must be on a stable pain medication routine without changes planned during the study and not use other pain therapies. Pregnant individuals, those with open wounds or cancerous growths on their feet, or severe hand dexterity issues due to conditions like MS are excluded.
What is being tested?
The trial is testing the Erchonia EVRL laser's effectiveness in providing temporary relief of foot pain caused by diabetic neuropathy against a placebo laser. Participants will use these treatments at home as prescribed and report their levels of foot pain.
What are the potential side effects?
Since this trial involves a low-level laser therapy device, side effects may include mild skin irritation at the treatment site. However, significant side effects are not commonly associated with such non-invasive treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 3 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS)
Secondary study objectives
Neuropathic Pain Symptom Inventory (NPSI)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Erchonia® EVRL™Active Control1 Intervention
The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device.
Group II: Placebo LaserPlacebo Group1 Intervention
The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light.

Find a Location

Who is running the clinical trial?

Erchonia CorporationLead Sponsor
44 Previous Clinical Trials
2,005 Total Patients Enrolled

Media Library

Erchonia® EVRL™ (Laser Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05291975 — N/A
Peripheral Neuropathy Research Study Groups: Erchonia® EVRL™, Placebo Laser
Peripheral Neuropathy Clinical Trial 2023: Erchonia® EVRL™ Highlights & Side Effects. Trial Name: NCT05291975 — N/A
Erchonia® EVRL™ (Laser Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05291975 — N/A
~17 spots leftby Dec 2025